Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.4 USD | -1.02% | -0.33% | +36.24% |
Financials (USD)
Sales 2024 * | 1.93B | Sales 2025 * | 2.79B | Capitalization | 12.42B |
---|---|---|---|---|---|
Net income 2024 * | 313M | Net income 2025 * | 955M | EV / Sales 2024 * | 5.9 x |
Net cash position 2024 * | 1.03B | Net cash position 2025 * | 2.54B | EV / Sales 2025 * | 3.53 x |
P/E ratio 2024 * |
40.6
x | P/E ratio 2025 * |
12.7
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.03% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | -1.02% | ||
1 week | -0.33% | ||
Current month | +3.73% | ||
1 month | +12.72% | ||
3 months | -2.40% | ||
6 months | +58.00% | ||
Current year | +36.24% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | +0.15% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 131.4 | -1.02% | 849,008 |
24-05-16 | 132.7 | +0.18% | 1,010,128 |
24-05-15 | 132.5 | -0.12% | 762,810 |
24-05-14 | 132.7 | +0.73% | 1,227,464 |
24-05-13 | 131.7 | -0.09% | 634,187 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.24% | 12.42B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
-24.95% | 8.23B |
- Stock Market
- Equities
- SRPT Stock